

# Buy

Last Price (Rp)	5,275
Target Price (Rp)	8,500
Upside/Downside	+61.1%
No. of Shares (mn)	3,681
Mkt Cap (Rpbn/US\$mn)	19,418/1,154
Avg, Daily T/O (Rpbn/US\$mn)	13.3/0.8

### **Key Financials:**

	2025F	2026F	2027F
EPS (Rp)	591.1	636.1	689.7
PER (x)	8.9	8.3	7.6
PBV (x)	0.8	0.7	0.7
EV/EBITDA (x)	3.8	3.1	2.3
Dividend yield (%)	1.6	1.8	1.9
ROAE (%)	9.4	9.4	9.4

# BRI Danareksa Sekuritas Analysts Richard Jerry, CFA

(62-21) 5091 4100 ext. 3511 Richard.jerry@brids.co.id

### Sabela Nur Amalina

(62-21) 5091 4100 ext. 4202 sabela.amalina@brids.co.id

# Indocement Tunggal Prakarsa (INTP IJ) Mar25 sales volume declines due to fewer working days; 3M25 was slightly below seasonality

- Mar25 domestic cement volume dropped -22.2% yoy due to fewer working days post-Eid.
- INTP sales fell -17.1% yoy, but 3M25 outperformed industry (-5.9% vs 7.8%), with market share rising to 30.7% in Mar25 (vs 28.8% on Mar24).
- The mgmt. sees early signs of April demand recovery; expects double-digit growth in domestic demand. Maintain Buy, TP Rp8,500.

# **Industry sales:**

- Mar25: 3.8 Mt (-18.4% mom/-22.2% yoy)
- 3M25: 13.2 Mt (-7.8% yoy)
- Bag: 2.6 Mt (-21.1% mom/-21.1% yoy)
- Bulk: 1.1 Mt (-11.3% mom/-24.6% yoy)

# **INTP sales:**

- Mar25: 1.2 Mt (-12.4% mom/-17.1% yoy)
- 3M25: 4.0 Mt (-5.9% yoy); 21% of FY25F (slightly below seasonality)
- Market share: 30.7% in Mar25 (vs Mar24: 28.8%)
- Domestic cement industry volume declined -22.2% yoy in Mar25, due to fewer working days following the Eid Al-Fitr holiday. Bag and bulk volumes fell -21.1% and -24.6% yoy, respectively.
- INTP's sales volume dropped -17.1% yoy (bag -13.0%, bulk -25.3%). However, 3M25 volume fell only -5.9% yoy, outperforming the industry's -7.8% yoy. Market share rose to 30.7% on Mar25 (vs 28.8% on Mar24).
- On the pricing front, we observe flattish to higher pricing for INTP's bag cement. Semen Tiga Roda price was at Rp1,487/kg (-0.6% mom) in Mar25, while Semen Rajawali improved by 3% mom and Semen Jempolan was relatively flattish at Rp1,076/kg (-0.4% mom). Semen Jempolan discount to Semen Tiga Roda stayed at ~28%, and has been relatively stable for past 3 months.
- The mgmt. noted early signs of demand recovery in Apr25, expecting double-digit growth in domestic consumption due to the timing shift of last year's Eid, which fell in the second week of April. We maintain our Buy rating with a TP of Rp8,500.

**Exhibit 1. INTP Monthly Sales Volume** 

Source: Company



**Exhibit 2. Industry Monthly Sales Volume** 



Source: Company

**Exhibit 3. INTP Historical Cement Price** 

Brand (Avg price Rp/kg)	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	%, MoM
Semen Tiga Roda	1,457	1,496	1,496	1,496	1,473	1,496	1,487	1,487	-0.6%
Semen Grobogan	1,263	1,281	1,281	1,281	1,281	1,281	1,281	1,281	0.0%
Semen Rajawali	1,213	1,231	1,257	1,265	1,270	1,231	1,270	1,270	3.2%
Semen Bosowa	1,461	1,461	1,461	1,461	1,461	1,461	1,461	1,461	0.0%
Semen Jempolan	-	1,080	1,010	1,098	1,098	1,080	1,076	1,076	-0.4%

Source: BRIDS Survey



# Equity Research - BRIDS First Take

Thursday, 17 April 2025

## **BRI Danareksa Equity Research Team**

Erindra Krisnawan, CFA Head of Equity Research, Strategy, Coal <a href="mailto:erindra.krisnawan@brids.co.id">erindra.krisnawan@brids.co.id</a>
Natalia Sutanto Consumer, Cigarettes, Pharmaceuticals, Retail <a href="mailto:natalia.sutanto@brids.co.id">natalia.sutanto@brids.co.id</a>

Niko Margaronis Telco, Tower, Technology, Media

Timothy Wijaya Metal, Oil and Gas Victor Stefano Banks, Poultry

Ismail Fakhri Suweleh Healthcare, Property, Industrial Estate Richard Jerry, CFA Automotive, Cement, Infrastructure

Ni Putu Wilastita Muthia Sofi
Naura Reyhan Muchlis
Sabela Nur Amalina
Kafi Ananta Azhari
Research Associate
Research Associate
Research Associate

natalia.sutanto@brids.co.id niko.margaronis@brids.co.id timothy.wijaya@brids.co.id victor.stefano@brids.co.id ismail.suweleh@brids.co.id richard.jerry@brids.co.id wilastita.sofi@brids.co.id naura.muchlis@brids.co.id sabela.amalina@brids.co.id

kafi.azhari@brids.co.id

# **BRI Danareksa Economic Research Team**

Helmy KristantoChief Economist, Macro Strategyhelmy.kristanto@brids.co.idDr. Telisa Aulia FaliantySenior Advisortelisa.falianty@brids.co.idKefas SidaurukEconomistkefas.sidauruk@brids.co.id

# **BRI Danareksa Institutional Equity Sales Team**

Yofi Lasini Head of Institutional Sales and Dealing vofi.lasini@brids.co.id Novrita Endah Putrianti Institutional Sales Unit Head novrita.putrianti@brids.co.id Institutional Sales Associate ehrliech@brids.co.id Ehrliech Suhartono Yunita Nababan Institutional Sales Associate yunita@brids.co.id Adeline Solaiman Institutional Sales Associate adeline.solaiman@brids.co.id Institutional Sales Associate andreas.kenny@brids.co.id **Andreas Kenny** Institutional Sales Associate **Christy Halim** christy.halim@brids.co.id Institutional Sales Associate Jason.joseph@brids.co.id Jason Joseph

# **BRI Danareksa Sales Traders**

Mitcha SondakhHead of Sales Tradermitcha.sondakh@brids.co.idSuryanti SalimSales Tradersuryanti.salim@brids.co.id

# INVESTMENT RATING

BUYExpected total return of 10% or more within a 12-month periodHOLDExpected total return between -10% and 10% within a 12-month periodSELLExpected total return of -10% or worse within a 12-month period

### Disclaimer

The information contained in this report has been taken from sources which we deem reliable. However, none of PT BRI Danareksa Sekuritas and/or its affiliated and/or their respective employees and/or agents makes any representation or warrant (express or implied) or accepts any responsibility or liability as to, or in relation to, the accuracy or completeness of the information and opinions contained in this report or as to any information contained in this report or any other such information or opinions remaining unchanged after the issue thereof.

We expressly disclaim any responsibility or liability (express or implied) of PT BRI Danareksa Sekuritas, its affiliated companies and their respective employees and agents whatsoever and howsoever arising (including, without limitations for any claims, proceedings, action, suits, losses, expenses, damages or costs) which may be brought against or suffered by any person as results of acting in reliance upon the whole or any part of the contents of this report and neither PT BRI Danareksa Sekuritas, its affiliated companies or their respective employees or agents accepts liability for any errors, omissios or mis-statements, negligent or otherwise, in the report and any liability in respoect of the report or any inaccuracy therein or omission therefrom which migh otherwise arise is hereby expresses disclaimed.

The information contained in the report is not to be taken as any recommendation made by PT BRI Danareksa Sekuritas or any other person to enter into any agreement with regard to any investment mentiond in this document. This report is prepared for general circulation. It does not have regards to the specific person who may receive this report. In considering any investments you should make your own independent assessment and seek your own professional financial and legal advice.